WVE

Wave Life Sciences Ltd.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.88
52-Week Range: $3.56 – $21.73
Market Cap: $744.84M
P/E (TTM): —
EPS (TTM): -1.08
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.61
PEG Ratio: —
Return on Equity: -67.42%
Return on Assets: -33.60%
Gross Margin: -202.00%
Operating Margin: -3248.33%
Profit Margin: 0.00%
Current Ratio: 9.99
Debt/Equity: 0.10
Total Debt: $43.59M
Free Cash Flow: $-128.78M
Revenue Growth: -73.90%
Earnings Growth: —
Enterprise Value: $297.83M

WVE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.65M	$113.31M	$108.30M	$42.73M
Research & Development	$115.86M	$130.01M	$159.68M	$182.78M
Selling, General & Admin	$50.51M	$51.29M	$59.02M	$75.33M
Operating Expenses	$166.37M	$181.30M	$218.71M	$258.11M
Operating Income	-$162.72M	-$68.00M	-$110.40M	-$215.38M
EBITDA	-$152.61M	-$58.79M	-$101.74M	-$206.53M
Pretax Income	-$161.14M	-$58.19M	-$97.01M	-$204.38M
Income Tax	$681.00K	-$677.00K	$0.00	$0.00
Net Income	-$161.82M	-$57.51M	-$97.01M	-$204.38M
Diluted EPS	-2.05	-0.54	-0.70	-1.21
Diluted Shares	78.86M	106.10M	138.28M	168.65M

WVE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$88.50M	$200.35M	$302.08M	$602.07M
Receivables	$0.00	$21.09M	$1.42M	$1.28M
Current Assets	$98.54M	$235.37M	$320.39M	$614.81M
Total Assets	$146.39M	$274.95M	$352.21M	$638.50M
Current Liabilities	$71.52M	$186.44M	$110.95M	$95.06M
Total Debt	$37.61M	$32.12M	$25.40M	$17.77M
Total Liabilities	$191.48M	$235.32M	$142.69M	$120.14M
Retained Earnings	-$967.34M	-$1.02B	-$1.12B	-$1.33B
Shareholders' Equity	-$45.09M	$39.63M	$209.51M	$518.36M
Working Capital	$27.02M	$48.93M	$209.44M	$519.75M

WVE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$127.78M	-$19.43M	-$151.03M	-$187.49M
Capital Expenditure	-$1.36M	-$1.11M	-$938.00K	-$718.00K
Free Cash Flow	-$129.14M	-$20.55M	-$151.96M	-$188.21M
Depreciation & Amortisation	$10.11M	$9.21M	$8.66M	$8.85M
Stock-Based Compensation	$17.19M	$9.79M	$13.14M	$24.97M
Investing Cash Flow	-$1.25M	-$1.11M	-$938.00K	-$718.00K
Financing Cash Flow	$67.19M	$132.53M	$253.89M	$488.24M
Net Change in Cash	-$61.85M	$111.99M	$101.93M	$300.02M

WVE Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$8.70M	$7.61M	$17.25M	$38.25M	$2.27M
Research & Development	$43.47M	$45.87M	$52.81M	$47.44M	$51.29M
Selling, General & Admin	$17.99M	$18.09M	$20.90M	$22.10M	$24.78M
Operating Expenses	$61.46M	$63.96M	$73.71M	$69.54M	$76.07M
Operating Income	-$52.76M	-$56.35M	-$56.47M	-$31.30M	-$73.80M
EBITDA	-$50.56M	-$54.12M	-$54.20M	-$28.99M	-$71.43M
Pretax Income	-$50.47M	-$53.85M	-$53.18M	-$26.09M	-$69.36M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$50.47M	-$53.85M	-$53.18M	-$26.09M	-$69.36M
Diluted EPS	-0.31	-0.32	-0.30	-0.13	-0.34
Diluted Shares	163.99M	167.74M	180.15M	200.17M	204.01M

WVE Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$208.48M	$196.22M	$602.07M	$544.59M	$368.01M
Receivables	$1.62M	$10.00M	$1.28M	$0.00	$888.00K
Current Assets	$223.56M	$215.49M	$614.81M	$561.27M	$507.51M
Total Assets	$252.35M	$241.38M	$638.50M	$583.54M	$558.32M
Current Liabilities	$87.41M	$85.90M	$95.06M	$49.83M	$50.81M
Total Debt	$21.71M	$19.77M	$17.77M	$15.71M	$43.59M
Total Liabilities	$113.09M	$116.83M	$120.14M	$71.81M	$104.80M
Retained Earnings	-$1.22B	-$1.27B	-$1.33B	-$1.35B	-$1.42B
Shareholders' Equity	$139.27M	$124.55M	$518.36M	$511.73M	$453.52M
Working Capital	$136.15M	$129.59M	$519.75M	$511.44M	$456.69M

WVE Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$46.01M	-$44.67M	-$33.78M	-$59.55M	-$53.58M
Capital Expenditure	-$306.00K	-$248.00K	—	-$438.00K	-$884.00K
Free Cash Flow	-$46.32M	-$44.91M	-$33.77M	-$59.99M	-$54.47M
Depreciation & Amortisation	$2.20M	$2.23M	$2.26M	$2.31M	$2.37M
Stock-Based Compensation	$6.20M	$6.47M	$7.35M	$9.06M	$10.73M
Investing Cash Flow	-$306.00K	-$248.00K	$1.00K	-$438.00K	-$123.45M
Financing Cash Flow	$11.69M	$32.69M	$439.69M	$2.53M	$330.00K
Net Change in Cash	-$34.63M	-$12.22M	$405.92M	-$57.46M	-$176.71M

Market Snapshot

About

Wave Life Sciences Ltd. is a clinical-stage genetic medicines company. The company develops stereopure oligonucleotide therapies targeting genetic diseases affecting the central nervous system, liver, and other organs.